Pfizer terminates an early-stage STING agonist trial

Pfiz­er’s pipeline pri­or­i­ti­za­tion has now turned to a STING ag­o­nist, with an ear­ly-stage study ter­mi­na­tion of the as­set, a spokesper­son con­firmed to End­points News. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.